AbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26
AbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26 Key Stories: AbbVie, the pharmaceutical giant, saw its shares surge an incredible 460% after successfully extending the patent life on its blockbuster drug, Humira. This strategic move allowed Abb
January 23, 20260
Audio is streamed directly from the publisher (insider.explainheart.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
AbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26
Key Stories:
- AbbVie, the pharmaceutical giant, saw its shares surge an incredible 460% after successfully extending the patent life on its blockbuster drug, Humira. This strategic move allowed AbbVie to mitigate what could have been a significant revenue “patent cliff”—a steep drop in sales once a drug’s patent expires and generic or biosimilar versions enter the market. The company used this extended period to develop new revenue streams, more than replacing Humira’s sales before its exclusivity eventually ended. This successful navigation now places a spotlight on other major pharmaceutical players. Merck, known for its oncology drug Keytruda, and Bristol Myers Squibb, another major drug developer, are both facing similar patent expirations on some of their key products. Investors will be closely watching how these companies strategize to extend their drug lifecycles or diversify their portfolios to avoid a similar revenue challenge in the coming years, making R&D pipelines and acquisition strategies critical for future share performance. Read more
Keywords: ABBV, BMY, Humira, MRK, R&D pipelines, biosimilars, drug patents, oncology, patent cliff, pharmaceutical stocks, share performance
The post AbbVie’s 460% Patent Win; Merck, BMY Next 01/23/26 first appeared on Rapid Money Radio.